you, Thank Tom.
that we February options an providing by of of year. this update the announced start me in Let on strategic review
goal value. Our to and reasonable remains shareholder all maximize consider to opportunities was
process. in of several X resources potential months, collaboration in have with effort our diligence. transactions adviser, And in time, specific have these survey past these financial considerable to and invested we Over terms of have then and conducting extensive we led of been this an activities, detailed
However, thus these has none Board far, the in determined opportunities of best time. shareholders at that interest of the are this
at This our going-forward reduction alignments. noted, a and Tom the substantial basis OpEx revenue on million a into operating by implemented first quarter. quarter of As over we expenses helps force in bring the lowered that $X.X better end per
focused not here, exploring actively And international are to monetize offset are are markets U.S. to particularly on that opportunities our assets we core noncore cash consumption. We to further focus.
in we large a addition with that of we as terminated And our ATM of engaged at-the-market new director. independent Joshua that And in in Horowitz facility. at one equity shareholders our April, also, discussions resulted time,
process set plan consummating will or pursuing and Our business transaction result to or completing company There the is the strategic yet other point, process a And also review this seeking process. that in have continue at specific deadline a can for we assurance strategic to to while operating efficiently be no the not outcome. particular return growth. this the
our now to business. Returning operating
noted, year-over-year growth in in As good our $XXX,XXX around reported Quell second the XX% quarter. to we business Tom of
a are While is absolute the of number modest, encouraging number there signs.
pause. in as a commercial entirely the First, it And over-the-counter from fact, decreased Quell fibromyalgia. has was been the in business growth
will We us OTC business, to sources give restart going are which now the of forward. planning X growth
are planning fourth active fibromyalgia quarter. of Quell both have and by business, We to the the OTC parts
year-over-year we the growth planned electrodes, was shortly. able Second, refills in drop was of reverse this Quell good growth. XX% business X-month growth, in Quell quarter, be we in we that with OTC is sold There X,XXX of the saw kits addition which the number starter Again, sold. to had which should XXX are and the revenue, to XXX% in
see is and Administration uptake Veterans as This exciting reimbursed. Quell of system. third, attractively And are refills opportunity in the starting fibromyalgia we health to an the device are
time, year expect of make to we'll this centers a few VA in are the be XXXX. at looking core for rest steadily VA grow but We and operating the focus to a the just
believe chemotherapy-induced clarity peripheral for forward indication. move We CIPN on have standing now we how neuropathy. with that CIPN to our
De a will indication We commercial XXXX introduce branding new this by a and of with end CIPN a devices of quarter oncology the large fourth if attractive the place. this year have falls everything launch If technology market. as Novo for a obtained by Quell potential will to make into submission like the into commercially
changes neuropathy. including business final compensation of types Advantage risk an for Tom, by is year-over-year Medicare adjustment year drop to phaseout to noted early DPNCheck due last of announced substantial year. As many the XXXX suffered a the of peripheral patient screening, expected
of will we to is continue next rotate DPNCheck customers year that expect markets. and beyond, some our other utilize we it into MA While imperative that
to the to Hopefully, have we We are year and of nevertheless, of a number working again, but progress. hope attractive of from scale quarters announcement opportunities indicators these business our the still over we up newer revenue of on as meaningful at least provide are channels. this that potential for pilots balance several updates the
XXXX. to prepared Scientific And side, meeting there comments, several June scientific prominent be and on and happy are take ADA in our Society the and the DPNCheck were the clinical at XXXX Those in abstracts Japanese May now. of Meeting we'll questions presented Diabetes
